Premium
Treatment and Prevention of Age‐Related Macular Degeneration
Author(s) -
Lim Lyndell,
Guymer Robyn H
Publication year - 2004
Publication title -
journal of pharmacy practice and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.222
H-Index - 22
eISSN - 2055-2335
pISSN - 1445-937X
DOI - 10.1002/jppr200434153
Subject(s) - macular degeneration , medicine , ophthalmology , etiology , degeneration (medical) , disease , family history , choroidal neovascularization , surgery
In Australia, age‐related macular degeneration is the leading cause of irreversible visual loss in individuals over 50 years of age. The complication of choroidal neovascularisation is responsible for the majority of severe visual loss in age‐related macular degeneration and current treatments concentrate on limiting the damage it causes. Until recently, argon laser photocoagulation was the only treatment for choroidal neovascularisation but collateral damage to the overlying retina has lead to newer treatments. Risk factor modification and prevention of age‐related macular degeneration is also a growing area of research, with increased age, family history and smoking identified as major risk factors. Some studies have suggested diet modification and supplements may have possible protective effects. Unfortunately, none of these treatments restore lost vision, or have a major impact on disease progression. Further research into the underlying aetiology and pathophysiology of age‐related macular degeneration is required to achieve more effective treatments and preventive measures.